Njira Lugogo, MD, from University of Michigan.

New subgroup data from the phase 2b AIRCULES trial show that lunsekimig, Sanofi's bispecific Nanobody targeting both thymic stromal lymphopoietin (TSLP) and interleukin-13 (IL-13), produced larger exacerbation reductions in patients with more severe or biomarker-high 

, according to Njira Lugogo, MD, MS, clinical professor of medicine and director of the Michigan Medicine Asthma Program at the University of Michigan. Lugogo discussed the data, presented at the 

European Respiratory Society (ERS) Congress 2026

 in Barcelona, Spain, held September 5 to 9, in an interview with 

AIRCULES Subgroup Data Show Lunsekimig Benefit Scales With Severity

“I'm really excited about lunsekimig specifically because this is the first bispecific biologic that we have in asthma,” she said, noting that most existing biologics target a single pathway despite evidence of redundant, overlapping inflammatory mechanisms in severe disease.

AIRCULES previously met its primary and key secondary endpoints compared with placebo, with lunsekimig added to standard of care in adults with moderate-to-severe asthma across the full range of fractional exhaled nitric oxide (FeNO) and eosinophil values.

 Lugogo said the annualized exacerbation reduction was about 39% in the overall population, rising to 55% at the highest dose tested (300 mg every 4 weeks). The effect was more pronounced in prespecified subgroups: patients with a history of more than 3 exacerbations had nearly an 80% reduction, those with high baseline FeNO had a significant exacerbation reduction alongside a lung function improvement and met the minimal clinically important difference on the Asthma Control Questionnaire, and patients with eosinophil counts above 300 cells/µL also showed a more robust response than the overall population, including improved forced expiratory volume in 1 second.

Lugogo said the dual-target mechanism has a specific rationale beyond simply combining 2 pathways: blocking TSLP upstream may help offset the eosinophil increase sometimes seen with IL-13 blockade alone, while both pathways have independently been linked to mucus reduction and lung function improvement. She also pointed to lunsekimig's potential to address comorbid type 2 conditions, such as sinonasal disease and atopic dermatitis, beyond asthma itself, based in part on her own clinical experience using dual-biologic combinations in patients with overlapping disease. On safety, she said the novel Nanobody platform showed a low rate of anti-drug antibodies and treatment-emergent adverse events similar between placebo and treatment arms, with no signals prompting concern heading into phase 3.

Lugogo said the subgroup data are meant to inform which patients should be prioritized in the phase 3 program and to help settle on a single dose going forward. She framed the results within a broader unmet need: only about 35% of patients with severe asthma currently achieve remission, and she said dual-pathway blockade could help expand that proportion. An early-intervention study of lunsekimig in high-risk patients, AIRLYMPUS, is expected to read out results next year.

Sanofi. Sanofi's lunsekimig met primary and key secondary endpoints in phase 2 respiratory studies in asthma and CRSwNP. Published April 7, 2026.

ClinicalTrials.gov. A study of lunsekimig (SAR443765) in adult participants with moderate to severe asthma (AIRCULES). Identifier: NCT06102005.

Articles

Lunsekimig, a bispecific Nanobody targeting TSLP and IL-13, showed enhanced exacerbation reduction in moderate-to-severe asthma, with larger effects in severe and biomarker-high subgroups. Overall annualized exacerbations fell ~39%, increasing to ~55% at 300 mg every 4 weeks. Patients with >3 prior exacerbations approached ~80% reduction, while high FeNO and eosinophils >300 cells/µL correlated with greater clinical benefit, including improved FEV1 and ACQ minimal clinically important difference attainment. Safety appeared comparable to placebo with low immunogenicity.

Phase 2b subgroup data showed lunsekimig's exacerbation benefit scaled with asthma severity and biomarker levels.

Asthma

The HCPLive asthma page is a comprehensive resource for clinical news and insights on asthmatic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for allergic and severe asthma, and more.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

AIRCULES: Lunsekimig Benefit Scales With Severity, With Njira Lugogo, MD

One interesting take-home point is how nonspecific some of the presenting symptoms can be. People with rare diseases tend to have a lot of false starts before something is actually found, because common things being common, it's not the first thing that most people think about.

Closing the Diagnostic Delay Gap in IgA Nephropathy, With Gaia Coppock, MD

Gaia Coppock, MD, is an associate professor of clinical medicine in the Division of Renal-Electrolyte and Hypertension and an attending physician at the Hospital of the University of Pennsylvania in Philadelphia. She directs the hospital's Glomerular Disease Clinical Research Program and its Kidney Biopsy Group, and directs the Lupus Nephritis Program at the University of Pennsylvania School of Medicine. She discussed the findings and what they mean for nephrology practice in an interview with HCPLive.

A poster presented at GlomCon 2026, the annual meeting for glomerular disease specialists held in Maui, Hawaii, put new numbers behind a familiar concern in IgA nephropathy (IgAN): symptom-driven delays between first presentation and diagnosis. The Vertex Pharmaceuticals-sponsored study paired 20 qualitative interviews with a 106-patient survey of the IgAN journey. It builds on 

recent HCPLive coverage of diagnostic gaps in IgAN

Patients most often presented with hematuria or fatigue, symptoms Coppock said are easy to miss or misattribute; hematuria, for example, is frequently mistaken for a urinary tract infection. Abnormal labs, including elevated urine protein (82%) and hematuria (70%), were usually what triggered a nephrology referral, and wait times stretching toward a year can put a patient's diagnosis roughly two years behind symptom onset.

Coppock noted once patients reach a nephrologist, the workup typically moves quickly, but many still described feeling confused after diagnosis and turned to the internet or patient advocacy groups to fill gaps, even though about 85% named their doctor as their primary source of information, and 57% said they would rather get it from their nephrologist specifically.

The survey also found a gap between what patients want from treatment and what they feel they're getting: 80% wanted symptoms stopped, but only 49% felt therapy delivered, with similar shortfalls for slowing kidney function loss (78% vs 50%) and delaying dialysis (75% vs 50%). Closing this gap carries real stakes: time-averaged proteinuria above 0.5 g/day has been linked to a higher risk of kidney failure in adults with IgAN.²

Her message to primary care: even low suspicion for IgAN warrants a urine check and follow-up, because earlier recognition offers more treatment options and, in her view, more hope for preserving kidney function.

Editor’s Note: Coppock reports relevant disclosures with 

Bensouda M, Wade B, Burns J, et al. IgA Nephropathy Patient Experience: A Qualitative and Quantitative Mixed-Methodology Study. Poster presented at: GlomCon 2026; August 3-7, 2026; Maui, HI.

Shah A, Gagnon-Sanschagrin P, Bedard J, et al. Time-averaged proteinuria ≤0.5 g/day is associated with kidney failure in adult patients with IgA nephropathy in the US. Poster presented at: National Kidney Foundation Spring Clinical Meetings; 2026; New Orleans, LA.

Videos

A survey of patients with IgA nephropathy shows how nonspecific symptoms and long referral waits delay diagnosis by up to two years.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

IgA Nephropathy

The HCPLive Berger disease page is a resource for medical news and expert insights on IgA nephropathy. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in Berger disease, and more.

Mistaken for a UTI: Diagnosing IgA Nephropathy, With Gaia Coppock, MD

Emerging data on STAT6 pathway inhibition was among the most interesting themes at this year's 

 in Barcelona, Spain, held September 5 to 9, according to Njira Lugogo, MD, MS, clinical professor of medicine and director of the Michigan Medicine 

 Program at the University of Michigan. Lugogo discussed the mechanism in an interview with 

, pointing to new data on KT-621, Kymera Therapeutics' investigational oral STAT6 degrader, presented as a poster at the congress.

STAT6 Degraders: Accessible Biologic-Like Asthma Care? With Njira Lugogo, MD

STAT6 sits downstream of both interleukin-4 (IL-4) and interleukin-13 (IL-13) signaling, meaning it functions as a shared pathway before either cytokine's inflammatory effects are produced. Lugogo noted that dupilumab is currently the only approved therapy that blocks both IL-4 and IL-13 simultaneously, and it does so indirectly, by targeting the IL-4 receptor alpha subunit. 

“We could imagine a time where we have an oral drug that has the ability to replicate what we're doing with biologics, and that really opens the space entirely,” she said. 

In the phase 1b BroADen trial of KT-621 in patients with atopic dermatitis and comorbid respiratory disease, the subgroup with asthma had a median 56% reduction in fractional exhaled nitric oxide and a 100% Asthma Control Questionnaire-5 responder rate by day 29.

 Kymera is now running BREADTH, a placebo-controlled, dose-ranging phase 2b trial of KT-621 in moderate to severe eosinophilic asthma, with topline data on forced expiratory volume in 1 second expected in late 2027.

Lugogo outlined several ways an oral STAT6 degrader could fit into practice beyond simply mirroring existing biologics. One is as an add-on for patients already on a biologic who are only partial responders, particularly those with discordant upper and lower airway disease not addressed by their current mechanism. A second is as a pre-biologic option for patients who have maximized inhaled therapy but are not clear candidates for a biologic, or who live where biologic access is limited by logistical barriers such as cold-chain delivery. A third is in early intervention trials for high-risk populations, an area she said is drawing growing interest across several biologic classes and could benefit from a more accessible oral option. She also raised the possibility of using a STAT6 degrader as an inhaled corticosteroid (ICS)-sparing add-on therapy, given increasing attention to the safety trade-offs of sustained high-dose ICS exposure.

Lugogo said the underlying opportunity is one of access: targeted asthma therapy is currently reserved largely for the most severe patients, and an oral option could extend biologic-like benefit to a much broader population. “It's very early. It's emerging, but I think it's extremely promising,” she said, adding that she plans to closely follow the STAT6 field over the next several years.

Feldman MB, Gollob J, Dey J, Shi K, Agarwal S, Graham N, Mainolfi N. KT-621, an oral STAT6 degrader, in patients with moderate-to-severe atopic dermatitis and comorbid asthma or allergic rhinitis: safety and evidence of clinical activity across type 2 inflammatory diseases in a phase 1b trial. Poster PA5913. Presented at: European Respiratory Society (ERS) Congress 2026; September 5-9, 2026; Barcelona, Spain.

Kymera Therapeutics, Inc. Kymera Therapeutics announces presentations on KT-621, a first-in-class, oral STAT6 degrader, at the European Respiratory Society and European Academy of Dermatology & Venereology congresses. Published September 1, 2026.

Lugogo, ofUniversity of Michigan, discusses how oral STAT6 degraders like KT-621 could expand biologic-like asthma treatment beyond highest severity.

Tim Smith joined the MJH Life Sciences team in 2022 and is currently an associate editor for 

. He is also the executive producer of two podcasts: 

. Previously, he was the producer of the Lungcast podcast. He graduated from UC Berkeley and worked in multimedia journalism as a staff writer prior to joining MJH. You can contact him at tsmith@mjhlifesciences.com.

LEADderm 2026 in Newport Beach paired clinical pipeline updates with sessions on leadership, burnout, and career skills rarely covered in standard training.

Multiple interviews highlighted late-stage hidradenitis suppurativa and alopecia areata therapies, along with molluscum contagiosum's first FDA-approved at-home option.

Several dermatologists discussed nonclinical topics, including angel investing, social media strategy, and saying no as a leadership skill.

Dermatologists gathered in Newport Beach, California, for LEADderm 2026, a conference built around what organizers call the specialty's "missing curriculum": mentorship, negotiation, practice management, and other skills clinical training often overlooks. 

 sat down with several speakers on-site. Here is a recap of 7 standout conversations:

Why Molluscum No Longer Means 'Watch and Wait,' With Leon Kircik, MD

Leon Kircik, MD, of the Icahn School of Medicine at Mount Sinai, discussed why berdazimer topical gel, 10.3%, gives families their first FDA-approved, at-home molluscum contagiosum option after decades of reliance on irritating topicals or in-office procedures. He also pointed to alopecia areata as an area he finds especially exciting, citing 3 approved JAK inhibitors and hope for a future biologic option.

How Skin Angels Backs Dermatology's Next Innovators, With Ross Levy, MD

Ross Levy, MD, of Endeavor Health, described Skin Angels, a dermatology-focused angel investing network that has evaluated more than 300 companies. He encouraged early-career dermatologists to treat everyday clinical pain points as potential business ideas, and pointed to AI and topical immune-targeted therapies as areas to watch.

Why Dermatologists Should Have a Seat at the Investment Table, With Manju Dawkins, MD

Manju Dawkins, MD, a Skin Angels member and founder of needle-anxiety startup Thimble Health, echoed the case for clinician involvement in dermatology investing. She cited needle phobia as an underappreciated problem, affecting an estimated 60% of adults, and said she is watching for fewer-injection biologics and more oral treatment options ahead.

The Present and Future of Precision Medicine in Dermatology, With Peter Lio, MD

Peter Lio, MD, of Northwestern University, compared precision medicine's more advanced state in psoriasis with the continued unmet need in atopic dermatitis, arguing oncology remains furthest along in matching therapies to disease biology. He also praised the growing evidence base behind over-the-counter cleansers and moisturizers.

Resilience in Medicine, HS Treatments, and the Oral JAK Pipeline Today

Lisa Swanson, MD, of Ada West Dermatology, discussed oral JAK inhibitors advancing for hidradenitis suppurativa, including povorcitinib and upadacitinib, and flagged a pediatric treatment gap in alopecia areata for children under 12.

Reaching Patients Online and Avoiding Burnout, With Steven Daveluy, MD

Steven Daveluy, MD, of Wayne State University, made the case for dermatologists posting reliable, unpolished content to counter online misinformation. He also discussed reframing burnout through an "energy audit" that identifies which parts of a workday to delegate or automate.

Tips on Saying 'No' as a Dermatology Leader, With Adam Friedman, MD

Adam Friedman, MD, of George Washington University, discussed strategic refusal as an undertaught career skill, recommending clinicians delay on-the-spot answers and loop requesters back into the decision rather than delivering a flat no.

Together, the interviews reflect LEADderm's dual focus: pipeline therapies moving toward approval, and the leadership and communication skills increasingly seen as core to a dermatology career.

Editor's Note: This transcript has been edited for grammar and clarity using artificial intelligence tools.

LEADderm 2026 in Newport Beach emphasized dermatology’s “missing curriculum” alongside therapeutic innovation. Discussions highlighted berdazimer topical gel as the first FDA-approved at-home option for molluscum contagiosum and growing excitement in alopecia areata with multiple approved JAK inhibitors. Speakers from Skin Angels argued clinicians should engage in angel investing and product development, citing AI, topical immune-targeted therapies, and injection-sparing strategies. Additional themes included precision medicine gaps in atopic dermatitis, oral JAK momentum in hidradenitis suppurativa, combating misinformation online, burnout mitigation, and strategic leadership communication.

A recap of 7 standout interviews from LEADderm 2026, covering molluscum care, HS pipeline data, precision medicine, and dermatology leadership.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

LEADderm 2026 Recap: 7 Interviews Dermatologists Should Know

Ankeet Bhatt, MD, is a research scientist at Kaiser Permanente Northern California and an associate physician at Kaiser San Francisco Medical Center.

According to data from the ADHERE-ASCVD trial, adaptive digital outreach via texts, emails, and secure portal messaging can improve short-term statin refill in patients with or at high risk of 

atherosclerotic cardiovascular disease (ASCVD)

ADHERE-ASCVD: Digital Reminders Improve Refill Rates, Adherence to Statins in ASCVD

European Society of Cardiology (ESC) Congress 2026

 in Munich, Germany, by Ankeet Bhatt, MD, MBA, cardiologist and investigator at Kaiser Permanente and adjunct professor at the Stanford University School of Medicine, represent a substantial step forward in addressing nonadherence, which is among the leading causes of preventable cardiovascular events.

“We essentially did this with very little to no funding, utilizing routine health system workflows, and we were able to conduct this study within 60 days from protocol finalization to trial readout,” Bhatt told 

 in an exclusive interview. “I think that, in the context of an intervention that is basically free and systems already have the existing infrastructure and technology to deploy them, we were encouraged by our findings.”

ADHERE-ASCVD was a prospective, randomized, open-label, blinded endpoint trial aiming to evaluate and optimize patient-facing messaging strategies for statin refill and adherence. Bhatt and colleagues included patients ≥18 years within the Kaiser Permanente Northern California health system who had ASCVD or 

. Additionally, patients were required to have no statin prescription fill within the prior 3 months and adherence <80% in the prior 12.

Patients were randomized to 4 separate outreach strategies, including secure portal messaging, text message, non-secure email, or usual care (defined as no proactive outreach). Following a primary response window of 14 days, investigators assessed statin refill based on pharmacy dispensing records. Patients who refilled during this period would not receive further intervention, while those who did not were re-randomized to receive either a follow-up with the same modality, an alternative modality, or usual care.

A total of 20,604 patients were enrolled in the study. Of these, 3154 patients had established ASCVD while 17,450 were classified as high-risk. Mean age was 54.8 years (standard deviation [SD], 9 years), and 8437 patients (40.9%) were female. Mean baseline statin adherence was 54.8% (SD, 15.7%) and mean time since prior statin fill was 205.9 days (SD, 68.5 days).

Improving Statin Adherence Through Digital Reminders

Initial outreach increased 14-day statin refill by 14.4% compared to 12% with usual care (adjusted risk difference, 2.3%; 95% CI, 1.3-3.4; adjusted risk ratio, 1.2; 95% CI, 1.1-1.3). Among initial nonresponders, the second wave of outreach improved refill further by 13% compared to 10.4% with usual care (adjusted risk difference, 2.5%; 95% CI, 1.3-3.7; adjusted risk ratio, 1.25; 95% CI, 1.11-1.39).

Bhatt and colleagues noted that switching modalities did not improve refill over continuing with the same modality (13.2% vs 12.5%; adjusted risk ratio, 1.06; 95% CI, 0.94-1.17). Cumulative statin refill was also higher among patients receiving any digital outreach compared to those receiving usual communication over 28 days (24.9% vs. 21.2%; adjusted hazard ratio, 1.21; 95% CI< 1.13-1.3).

Ultimately, Bhatt and colleagues concluded that, while the study showed relatively modest gains in overall statin adherence and refill rates, the results reflect a simple and easy opportunity for everyday healthcare systems to improve adherence among this high-risk population. Bhatt further explains that digital reminders for statin refill are an accessible and effective method by which these systems can better serve their patients.

“I would encourage systems to use the modality that they have the most familiarity with, the one that they’ve already invested in the infrastructure for and see if the gains that we saw in our study are replicated in theirs,” Bhatt said. “I think we’ve shown that this can be done at very low cost, and you can get an answer within just a couple of months. If it’s not effective in your system, I think that is just as important as knowing if it is, because you can redeploy those efforts to other things that may produce and effect size that’s important for you.”

Editors’ Note: Bhatt reports disclosures with Amgen, AstraZeneca, Bayer, Merck, Novo Nordisk, Pfizer, and others.

Bhatt A. ADHERE-ASCVD: Adaptive Digital Outreach for Statin Adherence. Presented at the European Society of Cardiology (ESC) Congress 2026, Munich, Germany. August 28-31, 2026.

Bhatt AS, Liu VX, Sun B, et al. Digital Outreach to Improve Statin Refills in Patients With Low Statin Adherence: The ADHERE-ASCVD Randomized Clinical Trial. 

. August 29, 2026. Accessed September 9, 2026. 

Kaiser Permanente. Adherence to Dyslipidemia Therapy: Harnessing Evidence from Randomized Evaluations in AtheroSclerotic CardioVascular Disease (ADHERE-ASCVD). Updated July 6, 2026. Accessed September 9, 2026. 

https://clinicaltrials.gov/study/NCT07522645

Ankeet Bhatt, MD, MBA, discusses the effectiveness of text, email, and secure portal message reminders for encouraging patients to keep up with their treatment.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Atherosclerotic Cardiovascular Disease

Alexander Combes, PhD, discusses how kidney organoids could be used to screen and repurpose drugs for acute kidney injury.

Kidney Organoids May Speed AKI Drug Screening, With Alexander Combes, PhD

Owen Muir, MD, DFAACAP, FCTMSS, co-founder and chief medical officer at Radial.

SWIFT accelerated Deep TMS resolved suicidal ideation faster than standard dosing, Owen Muir, MD, says.

Psychiatry

Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.

Major Depressive Disorder

Major Depressive Disorder condition center page, resources on the topics of medical news and expert insight into depression can be found. Content includes articles, interviews, videos, podcasts, and breaking news on MDD research, treatment, and drug development.

Q&A: Accelerated TMS Speeds Suicidal Ideation Relief, With Owen Muir, MD

Leon Kircik, MD, on why an FDA-approved, at-home molluscum option changes practice, and what is exciting for him in dermatology.

Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

Catch up on data from some of the most impactful trials presented at the European Society of Cardiology Congress 2026.

Dyslipidemia

Cardiomyopathy

Heart Failure

The HCPLive heart failure page is a resource for medical news and expert insights on HF. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for heart disease, reduced and preserved ejection fraction, and more.

ESC 2026 Recap: 5 Practice-Changing Trials to Know

 Human kidney organoids reveal why proximal tubule cells resist full recovery after AKI, aiding drug screening research.

Kidney Organoids Show Persistent AKI Injury, With Alexander Combes, PhD

Sharmila Dorbala, MD, MPH, is the director of nuclear cardiology at Brigham and Women’s Hospital and the director of amyloidosis research at Mass General Brigham Heart & Vascular Institute.

Sharmila Dorbala, MD, MPH, discusses how this treatment and imaging strategy may lead to a diagnostic overhaul for patients with amyloidosis.

REVEAL: I-124 Evuzamitide PET/CT Specific, Sensitive for Cardiac Amyloidosis Diagnosis

Alex Hillenbrand is an assistant editor for 

. She earned her BA in English from Lafayette College in 2023 and went on to write for pop culture, entertainment, and sports media outlets before joining MJH Life Sciences in 2025. In her free time, Alex enjoys cooking, going on walks, and meeting new people. Contact her at mjhlifesciences.com.

SPY003 cut histologic disease activity by 10 points at 12 weeks, completing proof-of-concept for Spyre's IBD combinations.

Inflammatory Bowel Disease

On the HCPLive inflammatory bowel disease page, resources on the topics of medical news and expert insight into IBD can be found. Content includes articles, interviews, videos, podcasts, and breaking news on IBD and more.

Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

Ulcerative Colitis

Ulcerative Colitis condition center page, resources on the topics of medical news and expert insight into colitis can be found. Content includes articles, interviews, videos, podcasts, and breaking news on UC research, treatment, and drug development.

SPY003 Meets Primary Endpoint in Phase 2 Trial for Ulcerative Colitis

David T. Rubin, MD is a professor of medicine at the University of Chicago, director of the Inflammatory Bowel Disease Center, and chair of the International Organization for the Study of IBD (IOIBD).

David T. Rubin, MD, on the screening tools, direct questions, and therapy choices behind IBD's three tiers of remission.

Comprehensive Disease Control Starts With Asking, With David T. Rubin, MD

Chelsie Derman is an associate editor for 

who covers allergy and  psychiatry. She joined MJH Life Sciences in September 2023 after graduating from The College of New Jersey with a bachelor’s degree in journalism and professional writing. In her free time, she enjoys creative writing and reading.

Deucrictibant XR reduced HAE attack rates by 83% versus placebo in the pivotal phase 3 CHAPTER-3 study across all 3 HAE types.

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Deucrictibant XR Meets Primary Endpoint in HAE Prophylaxis

The FDA granted DT120 (lysergide) ODT Breakthrough Therapy designation for MDD, citing promising phase 3 Emerge data.

Latest News

AIRCULES: Lunsekimig Benefit Scales With Severity, With Njira Lugogo, MD

Mistaken for a UTI: Diagnosing IgA Nephropathy, With Gaia Coppock, MD

STAT6 Degraders: Accessible Biologic-Like Asthma Care? With Njira Lugogo, MD

LEADderm 2026 Recap: 7 Interviews Dermatologists Should Know

ADHERE-ASCVD: Digital Reminders Improve Refill Rates, Adherence to Statins in ASCVD